Freenome is a biotechnology company driven to provide the tools needed to detect, treat and prevent cancer using routing blood draw. This company was founded in 2014 by Gabe Otte, Riley Ennis, Charles Roberts and is headquartered in South San Francisco, CA. Freenome combines molecular biology with advanced computational biology and machine learning to help with early cancer detection.

Register for Details

For more details on financing and valuation for Freenome, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Freenome

Forge green plus iconForge green minus icon

What is Freenome's IPO price?

The IPO price for Freenome will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Freenome?

Freenome is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Freenome shares pre-IPO?

If you own Freenome pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Freenome a publicly traded company?

Freenome is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

What is Freenome's funding to date?

Freenome has raised $1.35B to date.
Forge green plus iconForge green minus icon

When was Freenome founded?

Freenome was founded in 2014.

Who are Freenome's major investors?

Fidelity Investments
Polaris Partners
S28 Capital
Ra Capital Management
AME Cloud Ventures
T. Rowe Price
ARTIS Ventures
Perceptive Advisors
Kaiser Permanente Ventures
Farallon Capital Management
Rock Springs Capital
Innovation Endeavors
StartX (Stanford-StartX Fund)
Janus Henderson Investors
EcoR1 Capital
Logos Capital
Soleus Capital
Sands Capital
Byers Capital
Catalio Capital Management
ArrowMark Partners
Agent Capital
Ridgeback Capital
Longevity Vision Fund
K50 Ventures
Asset Management Ventures
Roche Venture Fund
Verily Life Sciences
Intermountain Ventures
Squarepoint Capital

Freenome Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
2/15/2024 Series F $254MM raised $XXX.XX $XXX.XX
1/11/2022 Series E $290MM raised $XXX.XX $XXX.XX
12/7/2021 Series D $300MM raised $XXX.XX $XXX.XX
8/26/2020 Series C $270MM raised $XXX.XX $XXX.XX
7/24/2019 Series B $165MM raised $XXX.XX $XXX.XX
8/28/2017 Series A $69.62MM raised $XXX.XX $XXX.XX
6/19/2016 Series Seed-2 $5.55MM raised $XXX.XX $XXX.XX
5/6/2016 Series Seed-1 $800.02K raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: May 23, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.